CD34 and p53 Immunohistochemical Stains Differentiate Hypocellular Myelodysplastic Syndrome (hMDS) from Aplastic Anemia and a CD34 Immunohistochemical Stain Provides Useful Survival Information for hMDS
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The presence of significant dysplasia in bone marrow (BM) aspirates helps to distinguish between hypocellular myelodysplastic syndrome (hMDS) and aplastic ane- mia (AA). Occasionally, diluted BM aspirates make it difficult to recognize dysplastic changes and can also negatively affect the detection of cytogenetic abnormalities in hMDS. We evaluated the usefulness of CD34 and p53 immunoreactivity for discriminating between hMDS and AA and for estimating survival outcomes in hMDS patients. Methods: BM clot section (BMC) or BM biopsy (BMB) specimens were obtained from 64 hMDS/AA patients (33 with hMDS and 31 with AA) and seven controls. Immunohisto- chemical (IHC) staining for CD34 and p53 was performed by using the EnVision detection system (Dako, Denmark). We compared the results of IHC staining, BM findings, and chromosomal analyses, and determined overall survival outcomes. Results: The number of CD34- and p53-positive BM cells was higher among the patients with hMDS than among the patients with AA ( P <0.001 and P =0.001, respectively). hMDS patients with increased CD34-positive cells had significantly poorer survival out- comes compared with those with normal number of CD34-positive cells ( P =0.013). Conclusions: CD34 and p53 IHC stains of BMC or BMB provide useful information for dif- ferentiating between hMDS and AA. CD34 IHC staining of BMC or BMB also provides useful information for estimating survival outcomes in hMDS patients.
Abstract
Background: The presence of significant dysplasia in bone marrow (BM) aspirates helps to distinguish between hypocellular myelodysplastic syndrome (hMDS) and aplastic ane- mia (AA). Occasionally, diluted BM aspirates make it difficult to recognize dysplastic changes and can also negatively affect the detection of cytogenetic abnormalities in hMDS. We evaluated the usefulness of CD34 and p53 immunoreactivity for discriminating between hMDS and AA and for estimating survival outcomes in hMDS patients. Methods: BM clot section (BMC) or BM biopsy (BMB) specimens were obtained from 64 hMDS/AA patients (33 with hMDS and 31 with AA) and seven controls. Immunohisto- chemical (IHC) staining for CD34 and p53 was performed by using the EnVision detection system (Dako, Denmark). We compared the results of IHC staining, BM findings, and chromosomal analyses, and determined overall survival outcomes. Results: The number of CD34- and p53-positive BM cells was higher among the patients with hMDS than among the patients with AA ( P <0.001 and P =0.001, respectively). hMDS patients with increased CD34-positive cells had significantly poorer survival out- comes compared with those with normal number of CD34-positive cells ( P =0.013). Conclusions: CD34 and p53 IHC stains of BMC or BMB provide useful information for dif- ferentiating between hMDS and AA. CD34 IHC staining of BMC or BMB also provides useful information for estimating survival outcomes in hMDS patients.
참고문헌 (19)
- Orazi A, "Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens", Am J Clin Pathol, 107, pp.268~274 (1997)
- Orazi A, "Myelodysplastic syndromes", Am J Clin Pathol, 132, pp.290~305 (2009)
- Tuzuner N, "Hypocellular myelodysplastic syndromes (MDS): new proposals", Br J Haematol, 91, pp.612~617 (1995)
- Baur AS, "CD34", QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes, 2000, pp.64, 71~79
- Elghetany MT, "Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia", Ann Hematol, 77, pp.261~264 (1998)
- Totzke G, "P53 downregulation in myelodysplastic syndrome - a quantitative analysis by competitive RT-PCR", Leukemia, 15, pp.1663~1664 (2001)
- Lepelley P, "Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis", Leukemia, 8, pp.1342~1349 (1994)
- Brunning RD, "WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed", pp.88~93 (2008), IARC
- Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes", Blood, 120, pp.2454~2465 (2012)
- Bain BJ, "Bone marrow pathology. 4th ed", pp.166~238 (2010), Wiley-Blackwell
- Bain BJ, "Leukaemia diagnosis. 4th ed", pp.219~260 (2010), Wiley-Blackwell
- Brodsky RA, "Wintrobe’s clinical hematology. 12th ed", pp.1185~1195 (2009), Lippincott Williams & Wilkins
- Matsui WH, "Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes", Leukemia, 20, pp.458~462 (2006)
- Choi JW, "F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia", Int J Hematol, 75, pp.257~260 (2002)
- Elghetany MT, "p53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection", Leuk Res, 24, pp.975~977 (2000)
- Horny HP, "Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes", Leuk Res, 31, pp.1609~1616 (2007)
- De Raeve H, "Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies", Histol Histopathol, 19, pp.935~950 (2004)
- Gupta P, "Bone marrow angiogenesis in aplastic anemia - a study of CD 34 and VEGF expression in bone marrow biopsies", Hematology, 14, pp.16~21 (2009)
- Soligo DA, "CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes", Am J Hematol, 46, pp.9~17 (1994)